Milestones

1. Expansion of the group's transfer activity: i) consolidation of the collaboration with AM-PHARMA for the validation of patented miRNAs as biomarkers of response of a new drug for kidney damage; ii) start of collaboration with AMADIX, through the RETOS-Colaboración 2022 project.
2. Consolidation of the Personalised Medicine research line in colo-rectal cancer and new PI in the group, Dr Elisa Conde, due to the achievement of the DTS project: miRNaMut Platform. Consolidation of collaboration with Dr Carolina de la Pinta, Radiation Oncology, increasing the multidisciplinary nature of the group.
3. Generation of new intellectual property regarding the potential of miR326 as a new therapeutic target in colorectal cancer, by means of a European patent application, in collaboration with the Immunology Department.
4. Consolidation of the group's participation and relevance in national and international platforms and infrastructures: 1) EATRIS: new REDEMI4all project for drug repositioning in pancreatic cancer, consolidation of Dr García Bermejo as co-chair of the Biomarkers Platform and her new position as Scientific Director of the EATRIS Spain Node; 2) AMRI: European Alliance of EATRIS, BBMRI and ECRIN. BBMRI includes the National Platform for Biobanks and Biomodels; ECRIN includes the National Platform for Clinical Trials SCReen.
5. Consolidation of the group's participation in national and international cooperative research structures in Renal Diseases: RICOR2040, CAM Biomedicine Groups and Consortium for European projects ERANET- RD-JPI, in rare renal diseases.